Jonathan McNeill Sells Shares for Tax Withholding

Jonathan McNeill, President and COO of CRESCENT BIOPHARMA, INC., reported the sale of 20,549 ordinary shares on June 22, 2026. The shares were sold at a weighted average price of $17.99, with individual transactions ranging from $16.88 to $18.86. This sale was executed automatically to satisfy tax withholding obligations related to the settlement of restricted stock units granted on December 15, 2025, and March 17, 2025. The sale was conducted under a Rule 10b5-1 instruction adopted on February 25, 2026, with the sole intention of covering taxes due upon the vesting of these restricted stock units. Following the transaction, Mr. McNeill owns 139,158 shares.